BR112017016378A2 - composições da pró-droga de fumarato de monometila - Google Patents

composições da pró-droga de fumarato de monometila

Info

Publication number
BR112017016378A2
BR112017016378A2 BR112017016378-0A BR112017016378A BR112017016378A2 BR 112017016378 A2 BR112017016378 A2 BR 112017016378A2 BR 112017016378 A BR112017016378 A BR 112017016378A BR 112017016378 A2 BR112017016378 A2 BR 112017016378A2
Authority
BR
Brazil
Prior art keywords
monomethyl fumarate
prodrug compositions
fumarate prodrug
formula
compositions
Prior art date
Application number
BR112017016378-0A
Other languages
English (en)
Inventor
S. MANSER David
Kirtikumar Shah Hardik
K. PERKIN Kristopher
Browning Ivan
Original Assignee
Alkermes Pharma Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54066160&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017016378(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Limited filed Critical Alkermes Pharma Ireland Limited
Publication of BR112017016378A2 publication Critical patent/BR112017016378A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

a presente invenção apresenta composições farmacêuticas que compreendem compostos da fórmula (i) e métodos de tratamento de distúrbios neurológicos que compreendem a administração a um sujeito que necessite dele de uma composição farmacêutica que compreende um composto da fórmula (i).
BR112017016378-0A 2015-02-08 2015-03-10 composições da pró-droga de fumarato de monometila BR112017016378A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113496P 2015-02-08 2015-02-08
US62/113,496 2015-02-08
PCT/IB2015/000731 WO2016124960A1 (en) 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions

Publications (1)

Publication Number Publication Date
BR112017016378A2 true BR112017016378A2 (pt) 2018-03-27

Family

ID=54066160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016378-0A BR112017016378A2 (pt) 2015-02-08 2015-03-10 composições da pró-droga de fumarato de monometila

Country Status (24)

Country Link
US (3) US20160228376A1 (pt)
EP (1) EP3253377B1 (pt)
JP (3) JP2018503651A (pt)
KR (1) KR102487136B1 (pt)
CN (1) CN107205985A (pt)
AU (3) AU2015381240A1 (pt)
BR (1) BR112017016378A2 (pt)
CA (1) CA2972179C (pt)
CY (1) CY1124419T1 (pt)
DK (1) DK3253377T3 (pt)
EA (1) EA037666B1 (pt)
ES (1) ES2879611T3 (pt)
HR (1) HRP20211269T1 (pt)
HU (1) HUE055210T2 (pt)
IL (2) IL252962B (pt)
LT (1) LT3253377T (pt)
MX (1) MX2017009849A (pt)
PL (1) PL3253377T3 (pt)
PT (1) PT3253377T (pt)
RS (1) RS62186B1 (pt)
SG (3) SG10201907291QA (pt)
SI (1) SI3253377T1 (pt)
UA (1) UA121323C2 (pt)
WO (1) WO2016124960A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200094485A (ko) * 2019-01-30 2020-08-07 (주)애거슨바이오 모노메틸 푸마레이트 전구체 약물 화합물 및 이들의 약학적 조성물
WO2020198940A1 (zh) * 2019-03-29 2020-10-08 深圳仁泰医药科技有限公司 2-(2,5-二氧代吡咯烷-1基)乙基甲基富马酸酯的晶型a及其制备方法和应用
JP7224067B2 (ja) * 2019-05-31 2023-02-17 キュラクル カンパニー リミテッド フマル酸ジメチルを含有する腸溶性錠剤
WO2021053476A1 (en) * 2019-09-16 2021-03-25 Glenmark Life Sciences Limited Process for preparation of diroximel fumarate
KR102566549B1 (ko) * 2021-06-08 2023-08-14 제이투에이치바이오텍 (주) 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
EP4355730A1 (en) * 2021-06-15 2024-04-24 Biogen MA Inc. Synthetic preparation for diroximel fumarate

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482547A (en) * 1982-08-26 1984-11-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted-1,3,4-benzotriazepines
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
PL392748A1 (pl) 2001-01-12 2011-05-09 Fumapharm Ag Amidy kwasu fumarowego
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
ES2297461T3 (es) 2003-09-09 2008-05-01 Fumapharm Ag Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
ES2523796T1 (es) 2004-10-08 2014-12-01 Forward Pharma A/S Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2006093353A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
US20080299196A1 (en) 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
EP2019671B1 (en) 2006-05-05 2014-09-24 The Regents Of The University Of Michigan Intermediates for the preparation of bivalent smac mimetics
JP2012525385A (ja) 2009-04-29 2012-10-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経変性および神経炎症の治療
JP5733930B2 (ja) * 2009-09-09 2015-06-10 武田薬品工業株式会社 固形製剤
SG11201404705YA (en) * 2012-02-07 2014-10-30 Biogen Idec Inc Pharmaceutical compositions containing dimethyl fumarate
CA2882713A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
DK2970101T3 (en) 2013-03-14 2018-08-20 Alkermes Pharma Ireland Ltd PRO-DRUGS OF FUMARATES AND THEIR USE IN TREATING DIFFERENT DISEASES
EP3027767A1 (en) 2013-08-01 2016-06-08 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CN104027311A (zh) * 2014-05-09 2014-09-10 万特制药(海南)有限公司 一种含有富马酸二甲酯的肠溶缓释微丸
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques

Also Published As

Publication number Publication date
CA2972179A1 (en) 2016-08-11
US20220257520A1 (en) 2022-08-18
EA037666B1 (ru) 2021-04-28
KR102487136B1 (ko) 2023-01-10
LT3253377T (lt) 2021-08-25
SI3253377T1 (sl) 2021-08-31
AU2015381240A1 (en) 2017-07-06
SG10201907291QA (en) 2019-09-27
US20160228376A1 (en) 2016-08-11
HUE055210T2 (hu) 2021-11-29
EP3253377A1 (en) 2017-12-13
ES2879611T3 (es) 2021-11-22
JP2018503651A (ja) 2018-02-08
MX2017009849A (es) 2017-12-11
IL252962B (en) 2022-07-01
EA201791432A1 (ru) 2017-12-29
AU2019200868A1 (en) 2019-02-28
SG11201705124QA (en) 2017-07-28
JP2019031550A (ja) 2019-02-28
PT3253377T (pt) 2021-07-14
AU2020205237A1 (en) 2020-07-30
CN107205985A (zh) 2017-09-26
CY1124419T1 (el) 2022-07-22
PL3253377T3 (pl) 2021-09-27
DK3253377T3 (da) 2021-07-12
KR20170115044A (ko) 2017-10-16
IL287830A (en) 2022-01-01
JP2020203951A (ja) 2020-12-24
CA2972179C (en) 2021-10-26
EP3253377B1 (en) 2021-05-12
WO2016124960A1 (en) 2016-08-11
HRP20211269T1 (hr) 2022-01-21
UA121323C2 (uk) 2020-05-12
RS62186B1 (sr) 2021-08-31
US20190247315A1 (en) 2019-08-15
AU2019200868B2 (en) 2020-05-14
JP7145918B2 (ja) 2022-10-03
AU2020205237B2 (en) 2022-04-14
SG10201907289VA (en) 2019-09-27
IL252962A0 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
ECSP17028463A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1
CR20150571A (es) Compuestos y composiciones terapéuticos
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201500926A1 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
GEP201706663B (en) Novel composition for nonalcoholic fatty liver disease (nafld
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
CR20160394A (es) Heteroaril amidas como inhibidores de agregación de proteína
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
CO6700824A2 (es) 2-oxi-quinolina-3- carboxamidas sustituidas como moduladores kcnq2/3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]